Next Phase Newsletter

A European focused venture capital firm founded in 2015 with partners based in Europe and US. The firm has a current fund which is actively investing in Spain, Portugal, the UK, and Ireland. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in series A & series B financings as a Lead or co-Lead with investments ranging from €3 million to €8 million over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over next 4 years. The firm will only invest in private companies. 
 
The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is strongly interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platform and analytics areas, such as big data-driven technologies on complex medical research. 
 
The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital arm of a global pharmaceutical company with a market cap exceeding $8 million, is actively investing in the early-stage healthcare sector. The firm focuses on seed-stage opportunities, with the initial investment range broadly, spanning up to several million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly financial driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A global angel investment group was created to leverage cross-pacific business opportunities by investing in early stage life science and healthcare companies, with an Asia connection. The firm invests in companies that are interested in performing development work in China, or commercializing their products in Asia;  the firm makes use of relationships with Asia-based life science service providers to guide portfolio companies through the development process , and also assists companies with the Chinese regulatory process. The firm is pre-venture capital and can contribute business, scientific and regional expertise to companies to improve probability for success. 
 
The firm will consider opportunities across the life science space, and is primarily focused on diagnostics and devices but also invests in therapeutics and life science tools.  The firm generally invests in companies with products with strong animal data, and which are addressing a significant health problem in China (such as cancer, cardiovascular and metabolic diseases, infectious diseases, and also CNS disorders in some circumstances).  Companies which have already attained approval in a market outside China may be of interest. 
 
The firm invests in early stage deals.  The firm only invests in companies that are interested in performing development work in China, or commercializing their products in China; the firm makes use of relationships with China-based life science service providers to guide portfolio companies through the development process and obtain matching government funds in China, and also assists companies with the Chinese regulatory process. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact investor focused on pediatric indications is willing to invest in companies in therapeutics, diagnostics, medical devices or digital health that help improve pediatric care. As an impact fund, the firm donates 10% of the General Partner’s Carry Interest to fund pediatric research. The firm generally makes initial investments of $3-5M and will invest globally. The firm looks to invest in 12-15 companies out of their first fund. 
 
Within pediatric indications, the firm is interested in Oncology, Infectious Diseases and select Rare/Orphan indications. The firm will consider any technology that helps move care forward in these areas, either directly, as a therapeutic or other treatment device or diagnostic, or indirectly, as a digital health technology that helps support care or complements treatment. For therapeutics, the firm will invest in companies that are 12-18 months from IND. For diagnostics and medical devices, the firm would like to see a proof of concept or prototype. For digital health, some post pilot sales or evidence of market traction is preferred, as is a partnership with a strategic partner, with validation of the technology. 
 
The firm can lead or co-invest, and looks to be a board observer for every portfolio company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Established in 2021, a USA-based venture capital firm is specialized in investments within the neurotech and psychedelics sectors. The fund actively participates in pre-seed to seed financing rounds, with an initial investment averaging around $200k and the possibility of subsequent investments. The firm actively seeks opportunities in the United States. 
 
The firm actively seeks opportunities in psychoactive therapeutics, CNS therapeutics, neurotech, and techbio. The firm has a neuro focus, and is interested in technologies/products related to CNS disorders, neurodegenerative diseases, neurostimulation and modulation, psychoactive pharmacology, etc. The firm typically invests in drug/therapeutics and medical devices but not so much in digital health. Additionally, the firm looks for cutting edge technologies that demonstrate true, step change or cornerstone innovation instead of incremental improvements on best-in-class technologies. 

The firm is an active investor that supports their portfolio companies with their network and resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A corporate venture capital fund invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the corporation’s goal of helping save 1M lives annually by 2030. This fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm currently has 12 portfolio companies and is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An early-stage venture capital firm was founded in 2010 and based in the US. The firm is a generalist fund, looking to expand its footprint in life sciences, specifically data, diagnostics, and therapeutics in oncology.  The firm focuses on Pre-Seed, Seed, and Series A investments. Typical check size ranges from $500k-5M USD, leading rounds. The firm focuses on companies in the US. 
 
The firm invests in data, diagnostics and therapeutics, with a strong preference in oncology. The firm was one of the first institutional investors in Tempus, an AI-driven data and diagnostics platform, and Pathos, an AI-driven clinical stage therapeutics platform in oncology.  Within therapeutics, companies should be pre-Phase II and for data and diagnostics companies, in-development stages. 
 
The firm does not require to take a board or observer seat but often will. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.